SUPPLEMENTAL INFORMATION ON RANDOMIZATION
This study had a single blind placebo run-in period prior to randomization. After randomization, the study was performed in a double-blind fashion. This was followed by a single-blind placebo withdrawal period. During the placebo run-in and placebo withdrawal periods, only the subject was blinded to the treatment.
The investigator and study staff, the subjects, the monitors, Sponsor staff, and Contract Research Organizations involved in the conduct of the study remained blinded to the study treatment during the double-blind treatment period and until study closure. Sponsor staff responsible for clinical trial supply distribution were unblinded to ensure adequate distribution of study treatment.
The investigational treatment and its matching placebo placebos were indistinguishable. The active reference and its matching placebo placebos were also indistinguishable. Investigational treatment (or matching placebo) and active reference (or matching placebo) were similar, but not exactly the same, which is discussed under study limitations. 94.5 (9.9) Change from baseline -2.0 (7.1) -2.5 (7.7) -7.6 (7.8) -7.9 (9.9) -6.9 (7.5) -7.0 (10.3) -Placebocorrected -0.75 -5. Figure S1 . MCP-Mod Analysis for Change from Baseline to Week 8 in SiDBP (All Randomized Patients) -Quadratic Model.
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